{ "items": [ "\n\n
\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical Trials\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n28 June 2021
\n \n \n \nResearch on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical Trials\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n28 June 2021
\n \n \n \nThe University of Oxford in partnership with AstraZeneca began vaccinations on 27 June 2021 for a new phase in human trials to test a COVID-19 vaccine \u2018AZD2816\u2019 in volunteers against the B.1.351 variant of concern \u2013 commonly known as the Beta variant.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n28 June 2021
\n \n \n \nResearchers from the University of Oxford have today released their findings about the so-called \u2018correlates of protection\u2019 against symptomatic COVID-19; potentially a tool to speed up safe development of new vaccines which may assist regulators in assessing the likely potency of any new COVID-19 vaccine without the need for Phase III efficacy trial data.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Publication\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n21 June 2021
\n \n \n \nA new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n14 May 2021
\n \n \n \nFor the one in ten who say they won\u2019t take a COVID-19 vaccine, messaging that focuses on personal rather than collective benefits is more effective.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n13 May 2021
\n \n \n \nResearch, from Com-COV study comparing mixed dosing schedules of Pfizer / Oxford-AstraZeneca vaccines, shows increase in the frequency of mild-moderate symptoms in those receiving either mixed dosing schedule. Adverse reactions were short-lived, with no other safety concerns. Impact of mixed schedules on immunogenicity unknown as yet, with data to follow from this study.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n6 May 2021
\n \n \n \nAndrew Pollard writes about vaccine equity in his article for The Conversation.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Public Engagement\n \n \n \n \n Research\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n6 May 2021
\n \n \n \nDr Samantha Vanderslott and Dr Seilesh Kadambari discuss their collaborative approach to providing ethnic minority groups with information on vaccines.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n20 April 2021
\n \n \n \nThough the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical Trials\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n14 April 2021
\n \n \n \nResearchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n7 April 2021
\n \n \n \nMedical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n31 March 2021
\n \n \n \nThe new easy-to-produce test detects coronavirus spike-protein binding antibodies in people who have tested positive for COVID-19.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n25 March 2021
\n \n \n \nOur partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n22 March 2021
\n \n \n \n- Oxford-AstraZeneca coronavirus vaccine 79% effective against symptomatic COVID-19 overall \r\n- Vaccine 100% effective against severe or critical symptomatic COVID-19 \r\n- No safety concerns reported
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Research\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n24 February 2021
\n \n \n \nThe first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Research\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n5 February 2021
\n \n \n \nA preprint of ongoing work to assess effectiveness of Oxford\u2019s ChAdOx1 coronavirus vaccine shows that the existing vaccine has similar efficacy against the B.1.1.7 \u2018Kent\u2019 coronavirus strain currently circulating in the UK to previously circulating variants.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Clinical Trials\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n4 February 2021
\n \n \n \nThe University of Oxford is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n26 January 2021
\n \n \n \nToday, Andrew Pollard, Professor of Pediatric Infection and Immunity at the University of Oxford, and chief investigator of the trials of the ChAdOx1 nCoV-19 coronavirus vaccine, volunteered his time to help deliver live-saving Covid vaccinations at the newly opened NHS Vaccine Centre at the Kassam Stadium, Oxford.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n10 December 2020
\n \n \n \nUniversity of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Vaccinology\n \n \n\n \n\n\n
\n \n\n \n23 November 2020
\n \n \n \nThe University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.
\n \n\n \n \n